Digital genome engineering company Inscripta has appointed Sri Kosaraju as President and CEO. Kosaraju succeeds Kevin Ness, who has led the company since 2016 and will remain as an advisor.
“On behalf of the Inscripta Board of Directors, we are excited to welcome Sri, an exceptional leader with whom I have worked closely for many years,” said John Stuelpnagel, Chairman of the Board.
“In the same manner that Illumina revolutionized DNA sequencing over the last 10 years, we are excited for the automated, multiplexed, industrial-scale Onyx platform to revolutionize gene editing and genome engineering,” Stuelpnagel added.
Kosaraju currently serves on the Board of Directors and is the Chair of the Audit Committee of 10x Genomics and is on the Board of the non-profit Testing for America.
Before joining Inscripta, Kosaraju was President of Penumbra, a medical devices company, which he joined before their initial public offering as CFO in May 2015.
During his tenure, Penumbra experienced rapid growth with revenues increasing from $125 million to $547 million. Earlier, Kosaraju spent 16 years at J.P. Morgan, where he was most recently Head of Healthcare Equity Capital Markets and Co-Head of Technology Equity Capital Markets.
While at J.P. Morgan, he worked closely with and advised many emerging, high-growth life science and tech companies. He holds a B.S. from the Massachusetts Institute of Technology.
“I am impressed by the people and the transformational digital genome engineering technology. I am excited to see the significant positive impact that this breakthrough technology can have across diverse applications and industries including bio-industrial materials development and manufacturing, genome discovery, healthcare, and sustainability,” said Kosaraju.
